​

Enliven Therapeutics (ELVN) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

ELVN Stock Forecast

Enliven Therapeutics (ELVN) stock forecast, based on 9 Wall Street analysts, predicts a 12-month average price target of $76.29, with a high of $82.00 and a low of $70.00. This represents a 81.95% increase from the last price of $41.93.

$15 $29 $43 $57 $71 $85 High: $82 Avg: $76.29 Low: $70 Last Closed Price: $41.93

ELVN Stock Rating

Enliven Therapeutics stock's rating consensus is Buy, based on 9 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 9 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 9 0 9 Strong Sell Sell Hold Buy Strong Buy

ELVN Price Target Upside V Benchmarks

TypeNameUpside
StockEnliven Therapeutics81.95%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts2714
Avg Price Target$71.50$76.29$71.93
Last Closing Price$41.93$41.93$41.93
Upside/Downside70.52%81.95%71.55%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 26211---13
Sep, 26111---12
Aug, 26-10---10
Jul, 26-10---10
Jun, 26-9---9
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 19, 2026H.C. Wainwright$73.00$37.3295.61%74.10%
Oct 02, 2026Sean LaamanMorgan Stanley$70.00$46.2151.48%66.94%
Aug 18, 2026Salim SyedMizuho Securities$73.00$59.5422.61%74.10%
Aug 18, 2026Etzer DaroutBarclays$78.00$59.5431.00%86.02%
Aug 06, 2026Dara AzarStifel Nicolaus$82.00$60.6835.14%95.56%
Aug 06, 2026Michael SchmidtGuggenheim$78.00$59.7030.65%86.02%
Aug 06, 2026Goldman Sachs$80.00$59.7034.00%90.79%
Jul 21, 2026Salveen RichterGoldman Sachs$67.00$51.6729.67%59.79%
Jul 09, 2026Robert BurnsH.C. Wainwright$65.00$50.8027.95%55.02%
Jul 01, 2026Stifel Nicolaus$80.00$50.6857.85%90.79%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 19, 2026H.C. WainwrightBuyBuyhold
Oct 08, 2026GuggenheimBuyBuyhold
Oct 02, 2026Morgan StanleyOverweightinitialise
Aug 18, 2026William BlairOutperforminitialise
Aug 18, 2026BarclaysOverweightinitialise
Aug 06, 2026GuggenheimBuyBuyhold
Jul 21, 2026Goldman SachsBuyBuyhold
Jul 09, 2026H.C. WainwrightBuyBuyhold
May 12, 2026GuggenheimBuyinitialise
May 08, 2026Goldman SachsBuyBuyhold

Financial Forecast

EPS Forecast

Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.01$-1.89$-1.83---
Avg Forecast$-2.16$-1.91$-2.28$-2.65$-2.94$-2.96
High Forecast$-2.16$-1.87$-2.19$-1.73$-1.64$-2.96
Low Forecast$-2.16$-1.96$-2.45$-3.60$-3.74$-2.96
Surprise %-6.94%-1.05%-19.74%---

Revenue Forecast

$0 $3M $6M $9M $12M $15M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast--$8.33K$10.00K$10.00K$11.67M
High Forecast--$8.33K$10.00K$10.00K$11.67M
Low Forecast--$8.33K$10.00K$10.00K$11.67M
Surprise %------

Net Income Forecast

$-135M $-119M $-103M $-87M $-71M $-55M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-71.58M$-89.02M$-103.69M---
Avg Forecast$-76.87M$-67.95M$-82.33M$-94.79M$-95.51M$-105.34M
High Forecast$-76.87M$-66.38M$-77.67M$-61.44M$-58.14M$-105.34M
Low Forecast$-76.87M$-69.51M$-86.99M$-128.14M$-132.88M$-105.34M
Surprise %-6.87%31.02%25.95%---

ELVN Forecast FAQ

Is Enliven Therapeutics stock a buy?

Enliven Therapeutics stock has a consensus rating of Buy, based on 9 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 9 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Enliven Therapeutics is a favorable investment for most analysts.

What is Enliven Therapeutics's price target?

Enliven Therapeutics's price target, set by 9 Wall Street analysts, averages $76.29 over the next 12 months. The price target range spans from $70 at the low end to $82 at the high end, suggesting a potential 81.95% change from the previous closing price of $41.93.

How does Enliven Therapeutics stock forecast compare to its benchmarks?

Enliven Therapeutics's stock forecast shows a 81.95% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Enliven Therapeutics over the past three months?

  • October 2026: 15.38% Strong Buy, 84.62% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • September 2026: 8.33% Strong Buy, 91.67% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • August 2026: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Enliven Therapeutics’s EPS forecast?

Enliven Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $-2.65, marking a 44.81% increase from the reported $-1.83 in 2025. Estimates for the following years are $-2.94 in 2027, and $-2.96 in 2028.

What is Enliven Therapeutics’s revenue forecast?

Enliven Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $10K, reflecting a 0% decrease from the reported $0 in 2025. The forecast for 2027 is $10K, and $11.67M for 2028.

What is Enliven Therapeutics’s net income forecast?

Enliven Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $-94.79M, representing a -8.59% decrease from the reported $-104M in 2025. Projections indicate $-95.509M in 2027, and $-105M in 2028.